Lung Cancer | Specialty

Dr. Gerber on the Rationale to Combine Immunotherapy With Radiation in Lung Cancer

October 2nd 2020

David Gerber, MD, discusses the rationale to combine immunotherapy with radiation therapy in lung cancer.

Dr. Giaccone on Treatment Options in NSCLC

October 1st 2020

Giuseppe Giaccone, MD, PhD, discusses current treatment options in non–small cell lung cancer.

Brigatinib Boosts Intracranial PFS and Health-Related QoL in ALK+ NSCLC

October 1st 2020

Brigatinib demonstrated sustained improvements in overall and intracranial progression-free survival and health-related quality of life compared with crizotinib in patients with ALK-positive advanced non–small cell lung cancer.

NSCLC Treatment Portfolio Gains RET-Targeted Therapy

October 1st 2020

In an interview with OncologyLive®, Justin F. Gainor, MD, discusses the impact pralsetinib may have on the RET-altered NSCLC paradigm.

Dr. Reck on the Safety of Pembrolizumab in KEYNOTE-024 in Metastatic NSCLC

September 30th 2020

Martin Reck, MD, PhD, discusses the safety profile observed with of pembrolizumab versus chemotherapy in patients with metastatic non–small cell lung cancer in the phase 3 KEYNOTE-024 trial.

EGFR-Mutated NSCLC: Looking Ahead

September 29th 2020

RELAY Trial Regimen Adverse-Event Overview

September 29th 2020

TKI Plus Antiangiogenic Combination Therapy

September 29th 2020

TKI Combination Clinical Trials: Practical Implications in US and UK

September 29th 2020

EGFR TKI Plus Chemotherapy Combination Strategy

September 29th 2020

Data Updates From the GioTag Study

September 29th 2020

The Use of TKIs in Patients With Brain Metastases

September 29th 2020

Approved Frontline TKIs for EGFR-Mutated Disease

September 29th 2020

Molecular Testing Prior to Metastases

September 29th 2020

Metastatic NSCLC: The Role of Liquid Biopsy

September 29th 2020

Molecular Testing in Metastatic NSCLC

September 29th 2020

Dr. Levy on the Role of Dabrafenib/Trametinib in BRAF V600E-Mutant NSCLC

September 28th 2020

Benjamin P. Levy, MD, discusses the role of the combination of dabrafenib and trametinib in BRAF V600E-mutant non–small cell lung cancer.

Dissecting the Data With Immune-Based Combinations in Advanced Nonsquamous NSCLC

September 28th 2020

Jonathan Dowell, MD, discusses the data that support the use of chemoimmunotherapy in the frontline setting of nonsquamous NSCLC.

Leveraging Immunotherapy and Targeted Therapy for Cure in Lung Cancer

September 26th 2020

Efforts to leverage targeted therapy and immunotherapy, which have been approved modalities in advanced non–small cell lung cancer, are leading to improved survival in patients with advanced and earlier-stage disease.

Dr. Levy on the DFS Benefit Achieved With Adjuvant Osimertinib in EGFR+ NSCLC

September 25th 2020

Benjamin P. Levy, MD, discusses the disease-free survival benefit with adjuvant osimertinib in the phase 3 ADAURA trial.